FDA Approves Gilead's Daily HIV Pill to Simplify Treatment

A new antiretroviral pill has been introduced to broaden treatment options for people living with HIV. The medication is designed to appeal to patients who are currently managing well on a single‑tablet regimen, such as Biktarvy, and are interested in switching to a different therapeutic approach.

The pill offers an alternative for those who prefer a change in their medication schedule or who may experience side effects or drug interactions with their current regimen. By providing a new, single‑tablet option, clinicians can tailor therapy to individual patient needs while maintaining the convenience that has become a hallmark of modern HIV treatment.

This development underscores the ongoing effort to expand the arsenal of HIV therapies, giving patients and healthcare providers more flexibility in choosing the most appropriate regimen for long‑term viral suppression.